Search details
1.
Autophagy suppresses tumorigenesis through elimination of p62.
Cell
; 137(6): 1062-75, 2009 Jun 12.
Article
in English
| MEDLINE | ID: mdl-19524509
2.
Atg7 cooperates with Pten loss to drive prostate cancer tumor growth.
Genes Dev
; 30(4): 399-407, 2016 Feb 15.
Article
in English
| MEDLINE | ID: mdl-26883359
3.
Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805.
J Natl Compr Canc Netw
; 21(7): 725-731.e1, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37433436
4.
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Prostate
; 82(12): 1176-1185, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35538398
5.
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
BJU Int
; 129(6): 718-722, 2022 06.
Article
in English
| MEDLINE | ID: mdl-34480522
6.
Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis.
Genes Dev
; 27(13): 1447-61, 2013 Jul 01.
Article
in English
| MEDLINE | ID: mdl-23824538
7.
New developments in mechanisms of prostate cancer progression.
Semin Cancer Biol
; 57: 111-116, 2019 08.
Article
in English
| MEDLINE | ID: mdl-30213689
8.
Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
Prostate
; 80(16): 1429-1437, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32949185
9.
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
J Urol
; 203(4): 684-689, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31596672
10.
Association between age and sex and mortality after adjuvant therapy for renal cancer.
Cancer
; 125(10): 1637-1644, 2019 05 15.
Article
in English
| MEDLINE | ID: mdl-30620389
11.
Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
J Urol
; 201(1): 62-68, 2019 01.
Article
in English
| MEDLINE | ID: mdl-30130544
12.
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis.
Genes Dev
; 25(5): 460-70, 2011 Mar 01.
Article
in English
| MEDLINE | ID: mdl-21317241
13.
p62 as a therapeutic target for inhibition of autophagy in prostate cancer.
Prostate
; 78(5): 390-400, 2018 04.
Article
in English
| MEDLINE | ID: mdl-29368435
14.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 373(8): 737-46, 2015 Aug 20.
Article
in English
| MEDLINE | ID: mdl-26244877
15.
Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
J Urol
; 199(1): 53-59, 2018 01.
Article
in English
| MEDLINE | ID: mdl-28728992
16.
Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
Support Care Cancer
; 26(6): 1889-1895, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29274030
17.
Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805.
Qual Life Res
; 27(6): 1589-1597, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29508208
18.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet
; 387(10032): 2008-16, 2016 May 14.
Article
in English
| MEDLINE | ID: mdl-26969090
19.
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Oncologist
; 21(11): 1315-1325, 2016 Nov.
Article
in English
| MEDLINE | ID: mdl-27566247
20.
Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Gynecol Oncol
; 141(1): 2-9, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-27016222